Risicoscreening van geriatrische patienten bij ziekenhuisopname met een clinical rule op basis van het HARM-onderzoek

Risicoscreening van de geriatrische patient bij opname met behulp van een clinical rule op basis van de reslutaten van het HARM-onderzoek

Reuzenstap in verbetering medicatiebewaking

Beslissingsondersteunende systemen verbeteren de medicatieveiligheid. Dit is onderzocht door clinical rules voor lithium te formuleren. Het blijkt dat bij 76% van de lithiumgebruikers een medicatiefout te voorkomen zou zijn geweest

Strategy for implementation and First results of advanced clinical decision support in hospital pharmacy practice

Clinical decision support systems (CDSS) are the new generation clinical support tools that ‘make it easy to do it right’. Despite promising results, these systems are not common practice, although experts agree that the necessary revolution in health care will depend on its implementation. To accelerate adoption a strategy is handed for structured development and validation of CDSS' content (clinical rules). The first results show that the proposed strategy is easily applicable for creating specific and reliable rules, generating relevant recommendations

Ouder maar niet anders

Ouder worden gaat gepaard met allerlei fysiologische veranderingen, bijvoorbeeld in de nierfunctie. Toch zijn ouderen geen wezenlijk afwijkende patiëntengroep en het is dus niet nodig om voor hen aparte richtlijnen te ontwikkelen

Schizofrenie en antipsychotica: Samenhang met het metabool syndroom

BACKGROUND: Cardiovascular morbidity and mortality are higher in patients with schizophrenia than in the general population because the metabolic side-effects of antipsychotics and schizophrenia increase the risk of cardiovascular disease (CVD) and diabetes mellitus type 2 (DM2). The metabolic syndrome is defined in order to discover which patients have a high risk of developing CVD and DM2. AIM: To survey the current knowledge about the relationship between schizophrenia and the metabolic syndrome, the influence of the use of antipsychotics on the development of the metabolic syndrome, and the possible differences in the effects that first and second generation antipsychotics have on the syndrome. METHOD: The PubMed and Medscape databases were searched for relevant articles published between 2000 and July 2008. RESULTS: Schizophrenia and the use of antipsychotics increase the prevalence of abdominal obesity, dyslipidemia and DM2 (i.e. the metabole syndrome). Second generation antipsychotics tend to cause a marked increase in the prevalence of abdominal obesity and dyslipidemia, whereas first generation antipsychotics hardly have any of these effects. Both first and second generation antipsychotics increase the risk of DM2. CONCLUSION: The metabolic syndrome has a significant effect on the morbidity and mortality of patients with schizophrenia because it increases the risk they will develop CVD and DM2. The risk increases still further if patients are taking antipsychotics. The risk of CVD can be decreased if patients with schizophrenia are screened in time and are monitored regularly